Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

626 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.
Sension M, Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, González-García J, Donnelly A, Phiri P, Ledesma E, McGrath D; 067 Study Group. Sension M, et al. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):153-62. doi: 10.1097/QAI.0b013e3181a5701c. J Acquir Immune Defic Syndr. 2009. PMID: 19346966 Clinical Trial.
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Durant J, Ortega-Gonzalez E, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J, González-García J. Montes ML, et al. J Antimicrob Chemother. 2016 Jan;71(1):244-50. doi: 10.1093/jac/dkv323. Epub 2015 Oct 19. J Antimicrob Chemother. 2016. PMID: 26483516 Free article. Clinical Trial.
Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients.
Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-García J, Arnalich F, Mingorance J, Pintado Berniches L, Perona R, Arribas JR. Montejano R, et al. J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):102-109. doi: 10.1097/QAI.0000000000001391. J Acquir Immune Defic Syndr. 2017. PMID: 28418989 Free article.
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Fätkenheuer G, et al. N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154. N Engl J Med. 2008. PMID: 18832245 Free article.
Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in HIV-infected patients.
Guzmán-Fulgencio M, Jiménez JL, García-Álvarez M, Bellón JM, Fernández-Rodriguez A, Campos Y, Rodríguez C, González-Garcia J, Riera M, Viciana P, Muñoz-Fernández MÁ, Resino S. Guzmán-Fulgencio M, et al. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):178-83. doi: 10.1097/QAI.0b013e3182893f74. J Acquir Immune Defic Syndr. 2013. PMID: 23666137
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.
Berenguer J, Zamora FX, Carrero A, Von Wichmann MA, Crespo M, López-Aldeguer J, Aldámiz-Echevarría T, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Esteban H, Bellón JM, González-García J; GESIDA HIVHCV Cohort Study Group. Berenguer J, et al. J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):280-7. doi: 10.1097/QAI.0000000000000156. J Acquir Immune Defic Syndr. 2014. PMID: 25157646
Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients.
Carrero A, Berenguer J, Hontañón V, Navarro J, Hernández-Quero J, Galindo MJ, Quereda C, Santos I, Téllez MJ, Ortega E, Sanz J, Medrano LM, Pérez-Latorre L, Bellón JM, Resino S, Bermejo J, González-García J; GeSIDA 3603b Study Group. Carrero A, et al. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):292-300. doi: 10.1097/QAI.0000000000002260. J Acquir Immune Defic Syndr. 2020. PMID: 31913996
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
626 results